Exhibit 99.1

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated May 29, 2026 with respect to the Class A Ordinary Shares, par value $0.0001 per share, of Research Alliance Corporation III, a company organized under the laws of the Cayman Islands, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

BIOTECHNOLOGY VALUE FUND L P
 
By:

/s/ Mark N. Lampert

 
  Mark N. Lampert, Authorized Signatory
Date: 05/29/2026

 

BVF I GP LLC
 
By:

/s/ Mark N. Lampert

 
  Mark N. Lampert, Authorized Signatory
Date: 05/29/2026

 

BIOTECHNOLOGY VALUE FUND II LP
 
By:

/s/ Mark N. Lampert

 
  Mark N. Lampert, Authorized Signatory
Date: 05/29/2026

 

BVF II GP LLC
 
By:

/s/ Mark N. Lampert

 
  Mark N. Lampert, Authorized Signatory
Date: 05/29/2026

 

Biotechnology Value Trading Fund OS LP
 
By:

/s/ Mark N. Lampert

 
  Mark N. Lampert, Authorized Signatory
Date: 05/29/2026

 

BVF Partners OS Ltd.
 
By:

/s/ Mark N. Lampert

 
  Mark N. Lampert, Authorized Signatory
Date: 05/29/2026

 

BVF GP HOLDINGS LLC
 
By:

/s/ Mark N. Lampert

 
  Mark N. Lampert, Authorized Signatory
Date: 05/29/2026

 

 

 

BVF PARTNERS L P/IL
 
By:

/s/ Mark N. Lampert

 
  Mark N. Lampert, Authorized Signatory
Date: 05/29/2026

 

BVF INC/IL
 
By:

/s/ Mark N. Lampert

 
  Mark N. Lampert, Authorized Signatory
Date: 05/29/2026

 

LAMPERT MARK N
 
By:

/s/ Mark N. Lampert

 
  Mark N. Lampert
Date: 05/29/2026